Birabresib

Birabresib
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[(6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide;
CAS Number	202590-98-5 ;
PubChem CID	9936746;
ChemSpider	8112374;
UNII	X40LKS49S3;
KEGG	D10911;
Chemical and physical data
Formula	C25H22ClN5O2S
Molar mass	491.99 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C;
	InChI InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1; Key:GNMUEVRJHCWKTO-FQEVSTJZSA-N;

Birabresib (OTX-015, MK-8628)^[1] is an experimental small molecule inhibitor of BRD2, BRD3, and BRD4 under investigation for the treatment of cancer. It is in development by Merck & Co. It is currently in clinical trials for leukemia and glioblastoma.^[2]

References[edit]

^ "Birabresib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council.
^ "Birabresib - OncoEthix". AdisInsight. Springer Nature Switzerland AG.

[1] "Birabresib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council.

[2] "Birabresib - OncoEthix". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]